Get the Stockscreener App
5.34
5.74%
0.29
After Hours:
5.65
0.31
+5.81%
Mainz Biomed N V stock is traded at $5.34, with a volume of 352.12K.
It is up +5.74% in the last 24 hours and up +17.11% over the past month.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
See More
Previous Close:
$5.05
Open:
$5.15
24h Volume:
352.12K
Relative Volume:
2.69
Market Cap:
$11.86M
Revenue:
$895.50K
Net Income/Loss:
$-26.30M
P/E Ratio:
-3.2561
EPS:
-1.64
Net Cash Flow:
$-23.84M
1W Performance:
+21.09%
1M Performance:
+17.11%
6M Performance:
-61.02%
1Y Performance:
-86.79%
1-Day Range:
$5.10
$6.60
1-Week Range:
$4.20
$6.60
52-Week Range:
$3.65
$48.80
Mainz Biomed N V Stock (MYNZ) Company Profile
Name
Mainz Biomed N V
Sector
Industry
Phone
-
Address
-
Compare MYNZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
5.34 | 11.86M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
606.74 | 232.08B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
223.08 | 160.42B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
151.38 | 42.01B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
201.78 | 36.62B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
423.99 | 34.72B | 3.84B | 866.24M | 792.60M | 10.37 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-21-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-21-22 | Initiated | H.C. Wainwright | Buy |
Mainz Biomed N V Stock (MYNZ) Latest News
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Nigeria
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Launches Major U.S. Study for AI-Powered Colorectal Cancer Detection Test - StockTitan
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed partners with Quest for colorectal cancer screening test - Yahoo Finance
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed Forms Agreement with Quest Diagnostics to - GlobeNewswire
Mainz Biomed Partners with Quest Diagnostics for Major Colorectal Cancer Screening Study - StockTitan
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline - Investing.com
Mainz Biomed stock hits 52-week low at $4.3 amid sharp annual decline By Investing.com - Investing.com South Africa
Mainz Biomed Secures $8 Million in Follow-On Offering - TipRanks
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering - GlobeNewswire
Mainz Biomed Secures $8M Through Strategic Follow-on Offering with Dual-Warrant Structure - StockTitan
Mainz Biomed prices $8M offering of shares and warrants - MSN
Mainz Biomed Prices $8 Million Follow-On Offering to Boost Diagnostics Operations - TipRanks
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules - The Manila Times
Mainz Biomed Announces $8M Follow-On Offering with Dual Warrant Structure - StockTitan
Mainz Biomed Partners With Thermo Fisher To Advance Colorectal Cancer Screening - Contract Pharma
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Mainz Biomed stock hits 52-week low at $0.18 amid market challenges - Investing.com India
Mainz Biomed announces 1-for-40 reverse stock split - Medical Buyer
Mainz Biomed (NASDAQ:MYNZ) Shares Set to Reverse Split on Tuesday, December 3rd - Defense World
Mainz Biomed Announces Stock Split - GlobeNewswire
Mainz Biomed Announces 1-for-40 Reverse Split Amid Nasdaq Compliance Issues | MYNZ Stock News - StockTitan
Q3 EPS Estimates for Mainz Biomed Increased by HC Wainwright - Defense World
Mainz Biomed (NASDAQ:MYNZ) Rating Lowered to “Neutral” at HC Wainwright - Defense World
What You Didn’t Know About Mainz Biomed N.V (NASDAQ: MYNZ) This Week - Stocks Register
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test - Nasdaq
Mainz Biomed and Thermo Fisher Scientific sign a collaboration agreement - Wiley
Mainz Biomed Considers Reverse Stock Split for Nasdaq Compliance - TipRanks
MAINZ BIOMED NV- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - Citybuzz
Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening - Nasdaq
Mainz Biomed N.V. and Thermo Fisher Scientific Inc. Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets - Marketscreener.com
Mainz Biomed and Thermo Fisher Scientific Sign a - GlobeNewswire
Mainz Biomed Partners with Thermo Fisher for Next-Gen Cancer Screening Breakthrough | MYNZ Stock News - StockTitan
Mainz Biomed N V Stock (MYNZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):